Literature DB >> 20716449

Regulatory effect of vasoactive intestinal peptide on the balance of Treg and Th17 in collagen-induced arthritis.

Shaohua Deng1, Yebin Xi, Hong Wang, Jing Hao, Xiaoyin Niu, Weiyi Li, Yue Tao, Guangjie Chen.   

Abstract

Vasoactive intestinal peptide (VIP) is a well-known anti-inflammatory neuropeptide. The capacity of VIP can be exhibited through inhibiting inflammatory responses, shifting the Th1/Th2 balance in favor of anti-inflammatory Th2 immunity and inducing regulatory T cells (Tregs) with suppressive activity. In addition to pro-inflammatory Th1 response, Th17 are also believed to play important roles in the pathogenesis of rheumatoid arthritis (RA). In this study, we used collagen-induced arthritis (CIA) model in Wistar rats to investigate the role of VIP in the balance of CD4(+) CD25(+) Tregs and Th17 on RA. Data presented here showed that administration of VIP decreased incidence and severity of CIA. Disease suppression was associated with the upregulation of CD4(+) CD25(+) Tregs, downregulation of Th17- and Th1-type response and influence on the RANK/RANKL/OPG system. The results provide novel evidence that the therapeutic effects of VIP on CIA rats were associated with the balance of CD4(+) CD25(+) Tregs and Th17.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20716449     DOI: 10.1016/j.cellimm.2010.07.010

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  28 in total

Review 1.  Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions.

Authors:  Mario Delgado; Doina Ganea
Journal:  Amino Acids       Date:  2011-12-03       Impact factor: 3.520

Review 2.  Neuropeptide receptors as potential drug targets in the treatment of inflammatory conditions.

Authors:  Erika Pintér; Gábor Pozsgai; Zsófia Hajna; Zsuzsanna Helyes; János Szolcsányi
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

Review 3.  Manganese-Enhanced Magnetic Resonance Imaging for Detection of Vasoactive Intestinal Peptide Receptor 2 Agonist Therapy in a Model of Parkinson's Disease.

Authors:  Katherine E Olson; Aditya N Bade; Charles R Schutt; Jingdong Dong; Scott J Shandler; Michael D Boska; R Lee Mosley; Howard E Gendelman; Yutong Liu
Journal:  Neurotherapeutics       Date:  2016-07       Impact factor: 7.620

4.  Gene Deletion of VIP Leads to Increased Mortality Associated with Progressive Right Ventricular Hypertrophy.

Authors:  Anthony M Szema; Sayyed A Hamidi
Journal:  J Cardiovasc Dis       Date:  2014-04-01

Review 5.  Treg cells in rheumatoid arthritis: an update.

Authors:  Faye A H Cooles; John D Isaacs; Amy E Anderson
Journal:  Curr Rheumatol Rep       Date:  2013-09       Impact factor: 4.592

6.  Isorhamnetin attenuates collagen-induced arthritis via modulating cytokines and oxidative stress in mice.

Authors:  Xuewen Wang; Wei Zhong
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 7.  The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseases.

Authors:  D Ganea; K M Hooper; W Kong
Journal:  Acta Physiol (Oxf)       Date:  2014-12-11       Impact factor: 6.311

8.  [Effects of vasoactive intestinal peptide on airway inflammation and Th17/Treg balance in asthmatic mice].

Authors:  Li-Qin Ke; Feng-Mei Wang; Yun-Chun Luo
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2017-06

9.  Novel, biocompatible, and disease modifying VIP nanomedicine for rheumatoid arthritis.

Authors:  Varun Sethi; Israel Rubinstein; Antonina Kuzmis; Helen Kastrissios; James Artwohl; Hayat Onyuksel
Journal:  Mol Pharm       Date:  2013-01-23       Impact factor: 4.939

10.  Selective VIP Receptor Agonists Facilitate Immune Transformation for Dopaminergic Neuroprotection in MPTP-Intoxicated Mice.

Authors:  Katherine E Olson; Lisa M Kosloski-Bilek; Kristi M Anderson; Breha J Diggs; Barbara E Clark; John M Gledhill; Scott J Shandler; R Lee Mosley; Howard E Gendelman
Journal:  J Neurosci       Date:  2015-12-16       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.